Ionis locks in a USD 30 million upfront payment and tiered royalties of up to the mid-20% range from Italy-based Recordati (Milan: REC) for exclusive ex-US rights to zilganersen, an antisense oligonucleotide targeting GFAP mRNA in Alexander disease — a fatal leukodystrophy with no approved treatments. The deal is signed three months before the FDA's PDUFA action date of September 22, 2026, with Ionis retaining sole US commercial rights and global development leadership.
Under the license agreement, Recordati assumes responsibility for ex-US regulatory filings, country-level early access pathways, and commercialization. Ionis receives the USD 30 million upfront plus undisclosed milestone payments. The royalty ceiling in the "mid-20% range" sits at the high end of rare disease norms. Total deal value has not been disclosed. No equity component was included.
Deal context
Zilganersen is an antisense oligonucleotide designed to reduce excess production of glial fibrillary acidic protein (GFAP), which accumulates due to gain-of-function mutations in the GFAP gene in patients with Alexander disease (AxD). The pivotal study (NCT04849741), which completed enrollment in July 2024, met its primary endpoint — statistically significant stabilization of gait speed on the 10-Meter Walk Test at Week 61 — and demonstrated favorable safety. Ionis holds Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, and EMA Orphan Drug designation. AxD affects an estimated 1 in 1–3 million people worldwide, and zilganersen is the only clinical-stage program in the indication.
Industry and transaction context
The USD 30 million upfront could be viewed as relatively low for a near-approval ASO with Breakthrough Therapy designation. By comparison, Ionis received USD 280 million upfront from Ono Pharmaceutical for a global license to sapablursen, an ASO at Phase II with no pivotal data, in a deal worth up to USD 940 million. The disparity likely reflects AxD's ultra-small patient population, which structurally caps commercial ceiling even at orphan drug pricing, combined with a back-loaded economics structure weighted toward milestones and the elevated royalty rate.